Eastern Cooperative Oncology Group ECOG

Single-agent activity of paclitaxel was initially evaluated by the Eastern Cooperative Oncology Group (ECOG) in a select cohort of 34 patients with unresectable, recurrent, or metastatic disease (34). The overall response rate was 40% (4 CR, 8 PR). Myelosuppression was the primary toxicity. The median survival was 9.2 mo with a 1-yr survival of 33%. 

Source. Eastern Cooperative Oncology Group, "ECOG Performance Status," URL http //ecog.dfci.harvard.edu). 

Table 2.7.4. Patient s performance status according to Eastern Cooperative Oncology Group (ECOG) and Karnofsky score...

---